GTx begins next phase of clinical trials for prostate cancer.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011230:Precancerous Conditions / Q000188:drug therapy* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D017312:Toremifene / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D017312:Toremifene